IL6 and COVID-19: Tocilizumab was approved for treatment in patients with serious COVID-19 presenting elevated IL-6 levels by the Chinese National Medical Products Administration (NMPA) in March 2020, and this treatment has been proposed as a candidate therapy for severe COVID-19 [118, 119].